{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:06:11Z","timestamp":1791216371235,"version":"4.1.0"},"reference-count":42,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T00:00:00Z","timestamp":1162252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Serum levels of B\u2010cell activating factor belonging to the tumor necrosis factor family (BAFF), a potent B\u2010cell survival factor, are elevated in patients with systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis and systemic sclerosis (SSc). The objective of this study was to determine serum BAFF levels and relate the results to the clinical features in patients with organ\u2010specific autoimmune diseases of the skin, such as localized scleroderma and autoimmune bullous diseases. Serum BAFF levels were examined by enzyme\u2010linked immunosorbent assay in 44 patients with localized scleroderma, 20 with pemphigus vulgaris\/pemphigus foliaceus, 20 with bullous pemphigoid and 30 healthy controls. Twenty patients with SSc and 20 with SLE were also examined as disease controls. Serum BAFF levels were elevated in localized scleroderma patients compared with healthy controls. Concerning localized scleroderma subgroups, patients with generalized morphea, the severest form of localized scleroderma, had higher serum BAFF levels than linear scleroderma or morphea patients. The BAFF levels of generalized morphea were comparable with those of SSc or SLE. Furthermore, serum BAFF levels correlated positively with antihistone antibody levels and the severity of skin lesion as well as the number of skin lesions. By contrast, serum BAFF levels were not significantly elevated in patients with pemphigus or pemphigoid. These results suggest that BAFF may be contributing to autoimmunity and disease development in localized scleroderma.<\/jats:p>","DOI":"10.1111\/j.1600-0625.2006.00485.x","type":"journal-article","created":{"date-parts":[[2006,10,31]],"date-time":"2006-10-31T13:57:23Z","timestamp":1162303043000},"page":"87-93","source":"Crossref","is-referenced-by-count":56,"title":["Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ\u2010specific autoimmune diseases"],"prefix":"10.1111","volume":"16","author":[{"given":"Takashi","family":"Matsushita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyo","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Echigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Wayaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuka","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihide","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri844"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0214121"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.11.1747"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061965"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/35010115"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00598-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11354"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21526"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.168"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70217-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-849"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archderm.1987.01660270088021","article-title":"Antinuclear and anti\u2010single\u2010stranded DNA antibodies in morphea and generalized morphea","volume":"123","author":"Falanga V","year":"1987","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.771"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archderm.1994.01690100057009","article-title":"Antigen specificity of antihistone antibodies in localized scleroderma","volume":"130","author":"Sato S","year":"1994","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360815"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh487"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60503-9"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90360-B"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(99)00019-5"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12319337"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI8748"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3370"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.05.010"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780260506"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70217-X"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000246474"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3233(08)60517-3"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.1.91"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.08.021"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00160.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11432"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu1019oa"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00425-9"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"e_1_2_6_43_2","first-page":"S377","article-title":"Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose\u2010escalation study of LymphoStat\u2010B (human monoclonal antibody to BLyS) in SLE patients","volume":"48","author":"Furie R","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0625.2006.00485.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0625.2006.00485.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:26:54Z","timestamp":1697048814000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0625.2006.00485.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,31]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1111\/j.1600-0625.2006.00485.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0625.2006.00485.x","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,31]]}}}